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sociated with inferior OS (p = 0.044) but not in multivariable 
analysis (p = 0.46).  Conclusions: We did not find the clinical 
significance of incidental PC to be an independent predictor. 
However, the positive correlation between incidental PC and 
LVI of BC deserves further investigation. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Radical cystectomy (RC) represents the mainstay of 
treatment for muscle-invasive bladder cancer (BC)  [1, 
2] . Advanced pathological tumor and nodal stage as 
well as positive soft-tissue surgical margins (STSMs) are 
the main pathologic determinants of survival after RC 
 [3] . Since outcomes of patients can vary considerably 
inter-individually  [4] , it is essential to individualize 
treatment based on patient-centered risk factors in or-
der to selectively advocate the use of adjuvant modali-
ties after RC.
 Incidental prostate cancer (PC) is not an uncommon 
finding in RC specimens after BC surgery  [5] . The report-
ed rates of detection vary considerably (2–58%), which is 
mainly due to different sampling techniques  [6, 7] . While 
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 Abstract 
 Objective: The aim of the study was to evaluate the impact 
of the clinical significance of incidental prostate cancer (PC) 
on overall survival (OS) after radical cystoprostatectomy (RC) 
for bladder cancer (BC).  Methods: A total of 822 consecutive 
men underwent RC in 3 academic centers between 1996 and 
2011. The clinical significance of incidental PC was deter-
mined according to the Epstein criteria. The Kaplan–Meier 
analysis with log-rank was used to investigate the impact of 
PC on OS and univariate and multivariate Cox regression 
analyses for risk factors of OS. The median follow-up was 36 
months (interquartile range 10–49).  Results: Of the 822 men, 
117 (14.2%) had clinically significant, 243 (29.6%) insignifi-
cant and 462 (56.2) no PC at RC. Men with PC were at higher 
risk for lymphovascular invasion (LVI) of BC compared to 
men without PC (p < 0.001). The 5-year OS for men with clin-
ically significant, insignificant and no PC was 33.3, 51.3 and 
51.5%, respectively (p = 0.050). In the subgroup of pN0 pa-
tients (n = 601), clinically significant PC was significantly as-
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there are reports in literature that biochemical recurrence 
does not significantly impact on survival after RC  [8] , 
there is evidence that supports the assumption that the 
presence of incidental PC represents an indicator of ag-
gressive BC biology  [6] . In light of recent studies report-
ing on the altered androgen sensitivity of BC in advanced 
stages  [9, 10] , the question arises whether the presence 
and clinical significance of incidental PC is an indicator 
for adverse outcomes of patients with invasive BC. In or-
der to evaluate this hypothesis, we assembled a multi-in-
stitutional collaborative with the aim of determining the 
prognostic impact of incidental PC and its clinical sig-
nificance on survival after RC.
 Patients and Methods 
 This is a retrospective study representing data from 3 prospec-
tively maintained databases of 3 German tertiary care centers. This 
study was conducted according to the provisions of the local ethics 
committee on each study site and conforms to the provisions of 
the Declaration of Helsinki. A common database was generated. 
Through regular communications, all data inconsistencies were 
solved prior to final analysis.
 A total of 822 consecutive men treated with RC for BC between 
1996 and 2011 were included. None of these patients received neo-
adjuvant treatment. In all centers, RC included the removal of the 
tumor-bearing bladder, prostate, seminal vesicles and bilateral pel-
vic lymph nodes. Adjuvant and palliative chemotherapy for BC was 
administered at the discretion of the treating physician based on the 
findings of histopathologic analysis and follow-up investigations.
 For BC, the following clinical and pathologic parameters were 
assessed: age at RC, Eastern Cooperative Oncology Group (ECOG) 
performance status, pathologic tumor and nodal stage, STSMs, 
lymphovascular invasion (LVI), performance of postoperative 
(adjuvant and/or palliative) chemotherapy and histological sub-
type.
 For incidental PC, the following clinical and pathologic param-
eters were evaluated: preoperative digital rectal examination 
(DRE), preoperative prostate-specific antigen (PSA) level, prostate 
volume, prior transurethral resection of the prostate (TURP), any 
prostate biopsy prior to RC, pathologic tumor and nodal stage, 
STSMs, lymphatic invasion, vascular invasion, Gleason-Score and 
tumor volume.
 Histologic Assessment 
 The histologic assessment was performed at the center-specific 
pathology department by dedicated genitourinary pathologists and 
was based on the 1973 WHO grading system and TNM classifica-
tion as approved by the AJCC  [11] . The pathological macro- and 
microscopic evaluation of cystoprostatectomy specimens included 
cross-sectioning of the entire prostate at 4–5-mm intervals with im-
munohistochemical staining to identify the presence of bladder 
 [12] and PC  [13] . Prostate specimens were processed according to 
the Stanford protocol  [13] . Clinically significant PC was defined as 
a tumor with Gleason 4 or 5 pattern, stage  ≥ pT3a, PC lymph node 
metastasis, positive STSM or tumor volume >0.5 cm 3  [14] .
 Positive STSMs were defined as the microscopic presence of 
malignant cells at the resection margins. LVI was defined as the 
microscopic presence of malignant cells within an endothelial cell 
line  [15] and was separately reported for bladder and PC stage 
based on immunohistochemical analysis.
 Follow-Up 
 Electronic hospital charts and physician records were reviewed 
to determine clinical outcomes. In all participating centers, pa-
tients generally were seen postoperatively every 3–4 months for the 
first year, semi-annually for the second and third years and annu-
ally thereafter. For determining overall survival (OS), clinical out-
comes were measured from the date of RC to the date of death as 
determined by death certificates or hospital charts or the date of 
last follow-up when the patient had not experienced death  [16] . 
The median follow-up was 36 months (interquartile range (IQR) 
10–52).
 Statistical Analysis and Model Development 
 For univariate analysis, the chi-square test/Fisher exact test was 
used for nominal data and the Student’s t test for scaled data. The 
Kaplan–Meier plots were used to estimate OS using log-rank test-
ing. For univariate and multivariate analyses, Cox-proportional 
hazard analysis was carried out to evaluate risk factors for death. p 
values are 2-sided and p < 0.05 was considered significant. Statisti-
cal analysis was performed using JMP ® 11.0. Values are given as 
mean ± SEM for all normally distributed variables or as median 
(range) for non-normally distributed variables.
 Results 
 The clinical and pathologic characteristics of the 822 
patients are listed in  table  1 . Positive lymph nodes (all 
from BC) were histologically confirmed in 218 of the 822 
patients (26.5%; 90 with pN1, 122 with pN2 and 6 with 
pN3). The median number of retrieved lymph nodes at 
RC was 18 (IQR 10–25).
 Of the 822 patients, 360 (43.7%) were diagnosed with 
incidental PC at RC. The rates of incidental PC between 
the 3 centers were 47.6, 44.8 and 35.1%. Of the 360 pa-
tients with incidental PC, 243 (67.5%) had clinically in-
significant and 117 (32.5%) clinically significant PC. The 
rates of clinically significant PC were not different across 
centers (center I: 14.7%, center II: 14.4% and center III: 
13.3%, p = 0.54).
 Patients with significant PC were of higher age com-
pared to patients with insignificant PC and without PC 
(p < 0.001 between the 3 groups). Compared to the group 
of patients with insignificant and without PC, patients 
with significant PC had a positive DRE at RC (p < 0.001 
between groups), a history of prostate biopsy prior to RC 
(p = 0.015/p = 0.006) and higher preoperative PSA levels 
(available data on 477 patients; p = 0.002/p < 0.001).
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Table 1.  Univariate Pearson chi-square/Fisher exact test for clinical and pathological parameters in the 822 pa-
tients with BC according to the presence and significance of incidental PC at RC (bold values indicate a statisti-
cally significant difference)
BC and PC  BC 
without PC 
p value
insignificant PC significant PC p value
Number of patients, % 243 (29.6) 117 (14.2) 462 (56.2)
Age at RC, years
Median 68 71 <0.001 66 <0.001
IQR 60–73 67–74 57–71
ECOG performance status (at RC)
Mean 0.7 0.8 0.9
Median 1 1 0.58 1
IQR 0–1 0–1 0–1 0.20
Preoperative DRE
Positive 76 (31.3) 56 (47.9) 0.002 5 (1.1) <0.001
Negative 167 (68.7) 61 (52.1) 457 (98.9)
Preoperative PSA (n = 477), ng/ml
Mean 3.5 6.7 0.020 1.7
Median 2.5 3.2 1.0 <0.001
IQR 1.0–4.0 1.9–5.4 0.5–2
Prostate volume, ml
Mean 22 25 0.40 21 0.97
Median 19 27 24
IQR 5–33 15–33 8–34
TURP in history without malignancy
Yes 3 (1.2) 3 (2.6) 0.39 20 (4.3) 0.043
No 240 (98.8) 114 (97.4) 442 (95.7)
Prostate biopsy prior to RC
Yes 1 (0.4) 5 (4.3) 0.015 0 (0) 0.006
No 242 (99.6) 112 (95.7) 462 (100)
Number of retrieved lymph nodes at RC
Median 17 18 0.49 18 0.80
Mean 16.4 18.1 17.4
IQR 7–25 10–26 10–25
BC
pT-stage (BC)
pTX 1 (0.4) 0 (0) 0.19 1 (0.2) 0.42
pT0 25 (10.3) 11 (9.4) 47 (10.2)
pTa 5 (2.1) 5 (4.3) 18 (3.9)
pTis 16 (6.6) 12 (10.3) 38 (8.2)
pT1 32 (13.2) 14 (12.0) 59 (12.8)
pT2a 39 (16.1) 12 (10.3) 59 (12.8)
pT2b 14 (5.8) 15 (12.8) 36 (7.8)
pT3a 43 (17.7) 13 (11.1) 80 (17.3)
pT3b 33 (13.6) 14 (12.0) 48 (10.4)
pT4a 32 (13.2) 18 (15.4) 63 (13.6)
pT4b 3 (1.2) 3 (2.6) 13 (2.8)
≤pT2b 132 (54.3) 69 (58.2) 0.42 258 (55.8) 0.94
≥pT3a 111 (45.7) 48 (41.8) 204 (44.2)
pN-stage (BC)
pNX 0 (0) 0 (0) 0.16 0 (0) 0.88
pN0 179 (73.7) 88 (75.2) 337 (72.9)
pN1 30 (12.3) 11 (9.4) 49 (10.6)
pN2 34 (14.0) 16 (13.7) 72 (15.6)
pN3 0 (0) 2 (1.7) 4 (0.9)
STSM (BC)
pRX 1 (0.4) 0 (0) 0.44 3 (0.6) 0.96
pR0 219 (90.1) 102 (87.2) 411 (89.0)
pR1 22 (9.1) 15 (12.8) 46 (10.0)
pR2 1 (0.4) 0 (0) 2 (0.4)
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BC and PC  BC 
without PC 
p value
insignificant PC significant PC p value
LVI (BC)
LV0 100 (41.2) 55 (47.0) 0.99 237 (51.3) <0.001
LVI 95 (39.1) 52 (44.4) 107 (23.2)
LVX 48 (19.8) 10 (5.5) 118 (25.5)
Histology
Pure UC 208 (85.6) 99 (84.6) 0.23 358 (77.5) 0.17
Pure SCC 4 (1.7) 3 (2.6) 8 (1.7)
Pure AC 1 (0.4) 0 (0) 2 (0.4)
UC + SCC 10 (4.1) 4 (3.4) 9 (2.0)
Small cell 3 (1.2) 2 (1.7) 1 (0.2)
SCC + UC 0 (0) 3 (2.6) 7 (1.5)
Sarcomatoid + UC 3 (1.2) 0 (0) 2 (0.4)
UC + sarcomatoid 1 (0.4) 0 (0) 6 (1.3)
UC + AC 0 (0) 0 (0) 2 (0.4)
UC + small cell + sarcomatoid 0 (0) 1 (0.9) 0 (0)
Pure sarcomatoid 1 (0.4) 0 (0) 0 (0)
UC + SCC + AC 0 (0) 0 (0) 1 (0.2)
Clear-cell + SCC 0 (0) 0 (0) 0 (0)
Plasmozytoid 2 (0.8) 0 (0) 1 (0.2)
Micropapillary 0 (0) 0 (0) 3 (0.7)
Nested 0 (0) 0 (0) 1 (0.2)
Lymphoepithelioma-like 0 (0) 0 (0) 0 (0)
Unclassified/unknown 10 (4.1) 5 (4.3) 61 (13.2)
Postoperative chemotherapy (BC) (adjuvant + palliative)
Received 46 (18.9) 14 (12.0) 0.13 89 (19.3) 0.31
Adjuvant 22 (9.1) 6 (5.1) 26 (56.3)
Palliative 16 (6.6) 6 (5.1) 51 (11.0)
Adjuvant plus palliative 8 (3.3) 2 (1.7) 12 (2.6)
Not received 197 (81.1) 103 (88.0) 373 (80.7)
PC
pT-stage (PC)
pT2a 145 (59.7) 28 (23.9) <0.001
pT2b 18 (7.4) 8 (6.8)
pT2c 68 (28.0) 49 (41.9)
pT3a 4 (1.7) 21 (18.0)
pT3b 0 (0) 6 (5.1)
pT4 0 (0) 5 (4.3)
Not assessed 8 (3.3) 0 (0)
STSM (PC)
pRX 2 (0.8) 1 (0.9) <0.001
pR0 229 (94.2) 95 (1.2)
pR1 3 (1.2) 20 (17.1)
Not assessed 9 (3.7) 1 (0.9)
Lymphatic invasion (PC)
LX 4 (1.7) 0 (0) <0.001
L0 222 (91.4) 92 (78.6)
L1 3 (2.6) 21 (18.0)
Not assessed 14 (5.8) 4 (3.4)
Vascular invasion (PC)
VX 5 (2.1) 0 (0) <0.001
V0 223 (91.8) 108 (92.3)
V1 0 (0) 5 (4.3)
Not assessed 15 (61.7) 4 (3.4)
Gleason score
4 24 (9.9) 1 (0.9) <0.001
5 35 (14.4) 2 (1.7)
Table 1. (continued)
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 Patients with PC were at higher risk for LVI of BC 
compared to patients without PC (p < 0.001). Conversely, 
patients without PC had undergone significantly more 
likely a TURP (for benign prostatic syndrome without 
evidence of malignancy) in their history (p = 0.043).
 Compared to the group of patients with insignificant 
PC, men with significant PC exhibited higher PC tumor 
stages at RC, higher PC tumor volumes, higher Gleason-
Scores, a higher risk of positive STSMs (from PC) as well as 
lymphatic and vascular invasion by PC cells (all p < 0.001).
 In the entire cohort, the 5-year OS was 50.1%. The 
5-year OS for patients with significant, insignificant and no 
PC was 33.3, 51.3 and 51.5%, respectively (p = 0.050;  fig. 1 ).
 For the entire cohort (n = 822) of patients, inferior OS 
was significantly associated with advanced age (p  < 
0.001), histologic advanced BC tumor stage (p < 0.001), 
pathologically confirmed lymph node tumor involve-
ment of BC (pN+ vs. pN0 and pN2–3 vs. pN1; both p < 
0.001), positive STSMs of BC (p < 0.001), LVI of BC cells 
(p < 0.001), receipt of postoperative chemotherapy (p < 
0.001) and a trend toward significance for patients with 
significant PC versus insignificant/no PC (p = 0.050;  ta-
ble 2 ). Sub-analyzed for pN0-staged patients (n = 604), 
the presence of clinically significant PC correlated with 
inferior OS compared to insignificant PC/no PC (p  = 
0.044).
 On multivariate analysis, adjusted for all significant 
variables of univariate analysis, histologically confirmed 
advanced BC stage (p < 0.001), node-positive disease (p < 
0.001), positive STSMs (p < 0.001), presence of LVI (p < 
0.001) and advanced age at RC (p < 0.001) were associ-
ated with inferior OS ( table 2 ) whereas the clinical sig-
nificance of PC (p = 0.46) as well as the receipt of postop-
erative systemic chemotherapy were not (p = 0.79).
 Discussion 
 In the present study, we investigated the impact of 
incidental PC and its clinical significance on mortality 
in patients treated with RC for BC. Previous smaller 
BC and PC  BC 
without PC 
p value
insignificant PC significant PC p value
6 184 (75.7) 8 (6.8)
7 0 (0) 91 (77.8)
8 0 (0) 7 (6.0)
9 0 (0) 8 (6.8)
10 0 (0) 0 (0)
Tumor volume (PC), mm3
Mean 6 11 <0.001
Median 5 12
IQR 3–10 6–15
 AC = Adenocarcinoma; SCC = squamous cell carcinoma; UC = urothelial carcinoma. 
Table 1. (continued)
 Fig. 1. Kaplan–Meier analysis for OS according to the presence and 
significance of incidental PC at RC for BC (insignif. = insignificant; 
mo. = months; signif. = significant; p = 0.06 for significant vs. in-
significant/no incidental PC). 
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studies have suggested that the presence of incidental 
PC at RC impacts on OS  [17] . In this series, the rate of 
incidental PC was relatively high (43.7%). In prior se-
ries, a high variation in the rates of incidental PC at RC 
ranging between 2 and 58% have been reported  [6, 7, 18, 
19] .
 In order to define the clinical significance of incidental 
PC, we used the Epstein criteria as outlined above  [14] . 
These parameters have been consistently used in other 
series evaluating the clinical significance of incidental PC 
at RC  [7] . In the present study, the rate of clinically sig-
nificant PC was similar between centers (13–14%). This 
suggests that the histopathologic evaluation of PC foci 
was conducted in the same way in the 3 participating cen-
ters over the study period of 15 years.
 In order to better characterize each of the 3 groups, we 
conducted further analyses. We found that the presence 
and clinical significance of PC correlated with the perfor-
mance of any prostate biopsy prior to RC, positive DRE, 
higher age at RC and higher preoperative PSA values. As 
in our centers the diagnostic work-up with PSA and DRE 
was usually done a few days prior to RC, the treatment 
approach did not change for patients with suspicious 
findings. However, with regard to studies advocating 
prostate-sparing techniques to improve functional out-
comes after RC  [7, 20] , our findings confirm the current 
clinical practice to use these parameters in order to rule 
out the presence of significant PC at RC.
 In this study, mortality was significantly associated 
with age, advanced pathologic tumor and nodal stage, 
STSM, LVI and delivery of postoperative chemotherapy. 
These data underpin that the present cohort is compa-
rable to similar larger series in terms of its primary tumor 
characteristics  [3, 4] .
 We also found that node-negative patients with clini-
cally significant PC were at higher risk for death com-
pared to patients with insignificant or no PC. However, 
on multivariate analysis, only the classic pathological risk 
factors and age were associated with OS whereas clini-
cally significant PC was not.
 Nonetheless, an interesting, albeit surprising find of 
the present study was that LVI by BC cells as deter-
mined by immunohistochemistry was strongly associ-
ated with the presence of incidental PC. Of note, the rate 
of locally advanced BC and number of retrieved lymph 
nodes was not significantly different between the 3 
groups. Thus, the question arises whether and how the 
presence of incidental PC might facilitate lymphovascu-
lar invasion of BC cells. This hypothetical question can-
not to be adequately addressed based on the available 
retrospective data but deserves further basic research 
investigation. As recent data suggest an influence of the 
Table 2.  Univariate and multivariate Cox regression analyses of risk factors for death after RC in patients with 
BC (bold values indicate a statistically significant difference)
Parameter Univariable OS  Multivariable OS
RR (95% CI) p value  RR (95% CI) p value
Significant vs. insignificant PC/no PC 1.32 (1.00–1.75) 0.050 1.12 (0.82–1.51) 0.45
≥pT3a vs. ≤pT2b (BC) 3.74 (3.00–4.68) <0.001 2.52 (1.93–3.29) <0.001
Pathologic nodal stage
pN + vs. pN0 2.63 (2.11–3.27) <0.001 1.53 (1.19–1.98) <0.001
Positive vs. negative STSMs (BC) 4.45 (3.35–5.82) <0.001 2.50 (1.85–3.33) <0.001
LVI vs. LV0 (BC) 2.60 (2.04–3.32) <0.001 1.39 (1.07–1.82) <0.001
Receipt of postoperative chemotherapy
(no vs. yes) 2.14 (1.68–2.72) <0.001 1.05 (0.79–1.40) 0.79
Age, years
(continuously, total range of risk)
>66 vs. ≤66
5.42 (2.96–10.06)
1.68 (1.35–2.09)
<0.001
<0.001
4.41 (2.38–8.29) <0.001
ECOG performance status (at RC)
(continuously, total range of risk)
ECOG ≥1 vs. 0
3.04 (0.84–10.78)
1.11 (0.62–2.08)
0.08
0.74
– –
Preoperative PSA level, ng/ml
(continuously, total range of risk)
>4 vs. ≤4, ng/ml
2.38 (0.27–10.43)
1.13 (0.79–1.59)
0.38
0.47
– –
 RR = Relative risk. 
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androgen pathway during the development and pro-
gression of muscle-invasive BC  [9, 10] , this may repre-
sent a possible molecular link for the development of 
significant PC foci during progression of invasive BC 
cells.
 This study has limitations inherent to its retrospective 
and multicenter nature. One limitation of this study is that 
our multicenter database did not contain data for recur-
rence-free and cancer-specific survival of all centers. Inter-
estingly, we found that approximately 48% of significant 
PCs were palpable on DRE which may also be due to BC 
invasion as approximately 15% had pT4a BC. Conversely, 
the question arises whether transrectal biopsy in case of a 
positive DRE may be helpful in selecting patients who 
should be offered neoadjuvant treatment  [1] . Despite the 
fact that the rate of clinically significant PC was very simi-
lar between centers, one cannot rule out an interobserver 
variability in the pathological assessment of RC specimens. 
Although we report on the number of retrieved lymph 
nodes as a surrogate marker for the meticulousness of pel-
vic LND, its association to the anatomical extent of LND is 
limited  [21] . However, all patients were treated in academ-
ic centers by surgeons dedicated to the management of pa-
tients with muscle-invasive BC. Nonetheless, owing to 
these limitations, the results of this study await external 
validation.
 Conclusions 
 Although node-negative patients with clinically signif-
icant PC exhibited inferior OS in univariate analysis, this 
series did not find the clinical significance of incidental 
PC to be an independent predictor for OS after RC for BC. 
However, the positive correlation between incidental PC 
and LVI of BC deserves further investigation.
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